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Abstract
Introduction: The Rheumatoid Arthritis Impact of Disease (RAID) is a patient-reported outcome measure evaluating
the impact of rheumatoid arthritis (RA) on patient quality of life. It comprises 7 domains that are evaluated as
continuous variables from 0 (best) to 10 (worst). The objective was to define and identify cut-off values for disease
activity states as well as improvement scores in order to present results at the individual level (for example, patient
in acceptable state, improved patient).
Methods: Patients with definite active RA requiring anti-tumour necrosis factor (anti-TNF) therapy were seen at
screening, baseline and after 4 and 12 weeks of etanercept therapy. Answers to “Gold standard” questions on
improvement (MCII: Minimum Clinically Important Improvement) and an acceptable status (PASS: Patient
Acceptable Symptom State) were collected as well as the RAID score and Disease Activity Score 28- erythrocyte
sedimentation rate (DAS28-ESR). Cut-offs were defined by different techniques including empirical, measurement
error and gold standard anchors. The external validity of these cut-offs was evaluated using the positive likelihood
ratio (LR) based on the patient’s perspective (for example, patient’s global) and on low disease activity status (such
as DAS28-ESR).
Results: Ninety-seven (97) of the 108 recruited patients (age: 54 ± 13 years old, female gender: 75%, rheumatoid
factor positive: 81%, disease duration: 8 ± 7 years, CRP: 18 ± 30 mg/l, DAS28-ESR: 5.4 ± 0.8) completed the 12
weeks of the study. The different techniques suggested thresholds ranging from 0.2 to 3 (absolute change) and
from 6 to 50% (relative change) for defining MCII and thresholds from less than 1 to less than 4.2 for defining
PASS. The evaluation of external validity (LR+) showed the highest LR+ was obtained with thresholds of 3 for
absolute change; 50% for relative change and less than 2 for an acceptable status.
Conclusions: This study showed that thresholds defined for continuous variables are closely related to the
methodological technique, justifying a systematic evaluation of their validity. Our results suggested that a change
of at least 3 points (absolute) or 50% (relative) in the RAID score should be used to define a MCII and that a
maximal value of 2 defines an acceptable status.
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Introduction
During the last decade and in particular since the parti-
cipation of patients in different Outcome Measures in
Rheumatology (OMERACT) activities [1-3] there has
been growing interest in the assessment of rheumatoid
arthritis (RA) from the patient’s perspective. Apart from
patient-reported outcomes traditionally evaluated during
the current standard assessment of RA, namely patient
assessment of pain, functional disability and/or patient
global assessment [4,5], other health domains are also
important for the patient such as fatigue, wellbeing and
sleep pattern [6-8]. Under the umbrella of the European
League Against Rheumatism (EULAR), a patient-
reported composite index, the Rheumatoid Arthritis
Impact of Disease (RAID) score has been proposed and
validated [9-12]. This composite index includes seven
domains (pain, function, fatigue, physical and psycholo-
gical wellbeing, sleep disturbance and coping). Each
domain is evaluated using a single question answered by
a 0 to 10 numerical rating scale. Each domain also has a
specific weight assigned by a patient survey. The RAID
score is a continuous variable ranging from 0 (best) to
10 (worst) (Table 1).
In general, the results of clinical studies and trials are
reported at group level, for example by the mean change
from baseline and this makes determination of the rele-
vance of the results for an individual patient challenging.
In order to make interpretation easier, data may be pre-
sented at individual level by considering the proportion
of patients with an improvement above a threshold of
an important change from baseline. Moreover, apart
from the concept of improvement (’feeling better), the
concept of status (’feeling good’) has become increas-
ingly important [13]. In order to assess these individual
outcomes, continuous outcome measures (absolute
value or change in RAID score) for each patient must
be converted into a dichotomous variable (that is,
change from baseline above a clinically relevant cutoff
defining an important improvement from the patient’s
perspective, or absolute value below a clinically relevant
cutoff defining an acceptable or good condition from
the patient’s perspective). These cutoffs have been called
Minimal Clinically Important Improvement (MCII) for
improvement and Patient Acceptable Symptom State
(PASS) for status [14-17].
Three types of technique have been proposed to
determine thresholds. According to the first simple
empirical method, an absolute change of at least 1 or 2
points on a 0 to 10 scale [18,19] or a relative change of
at least 20, 30 or 50% [20,21] have been proposed as
thresholds for several patient-reported outcomes in
rheumatic disorders. The second technique considers a
change to be relevant when it exceeds the measurement
error [22]. The third technique uses a gold standard
Table 1 Rheumatoid Arthritis Impact of Disease questionnaire*
1. Pain
Circle the number that best describes the pain you felt due to your rheumatoid arthritis during the last week:
None 0 1 2 3 4 5 6 7 8 9 10 Extreme
2. Functional disability assessment
Circle the number that best describes the difficulty you had in doing daily physical activities due to your rheumatoid arthritis during the last week:
No difficulty 0 1 2 3 4 5 6 7 8 9 10 Extreme difficulty
3. Fatigue
Circle the number that best describes how much fatigue you felt due to your rheumatoid arthritis during the last week:
No fatigue 0 1 2 3 4 5 6 7 8 9 10 Totally exhausted
4. Sleep
Circle the number that best describes the difficulty the sleep difficulties (i.e., resting at night) you felt due to your rheumatoid arthritis during the last
week:
No difficulty 0 1 2 3 4 5 6 7 8 9 10 Extreme difficulty
5. Physical well-being
Considering your arthritis overall, how would you rate your level of physical wellbeing during the past week? Circle the number that best describe
your level of physical well-being:
Very good 0 1 2 3 4 5 6 7 8 9 10 Very bad
6. Emotional well-being
Considering your arthritis overall, how would you rate your level of emotional well being during the past week? Circle the number that best
describes your level of emotional well-being:
Very good 0 1 2 3 4 5 6 7 8 9 10 Very bad
7. Coping
Considering your arthritis overall, how well did you cope (manage, deal, make do) with your disease during the last week:
Very well 0 1 2 3 4 5 6 7 8 9 10 Very poorly
*adapted from Gossec L et al [30]
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anchor (usually the patient’s global assessment) to deter-
mine the threshold from the best ratio between sensitiv-
ity and specificity using the receiver operating
characteristic (ROC) curve [23], correct classification
probabilities [24] or the 75th percentile [14,15].
To our knowledge, despite the recognition of the
validity of the RAID questionnaire, no formal threshold
has been proposed to present results at the individual
level. Furthermore, although several techniques have
been used to establish threshold values as detailed
above, no comparison has been performed between
these techniques.
We were therefore prompted to conduct a study in
order to define and evaluate the validity of cutoffs for
the RAID score using the different techniques described
above.
Materials and methods
Study design
This study was a multi-center, open-label, single-arm
trial with a screening visit, baseline visit (assuming
patient disease activity was stable across the two visits)
and visits after 4 and 12 weeks of etanercept therapy
(clinicaltrials.gov allocated number NCT 00768053). For
each patient, written informed consent was obtained
according to the Declaration of Helsinki. The study was
approved by the Institutional Review Board of Cochin
Hospital, Paris, France.
Inclusion criteria
To be eligible for the study, patients had to have definite
RA fulfilling the 1987 criteria of the American College
of Rheumatology [21]. The disease had to be active
according to the following definition: Disease Activity
Score 28-erythrocyte sedimentation rate (DAS28-ESR) >
3.2 and at least one of the following: ≥ 4 swollen joints
or C-reactive protein (CRP) ≥ 10 mg/l or ESR ≥ 28
mm/1st H, and the patient had to be eligible for tumor-
necrosis factor (TNF) blocker therapy as recommended
by the French Society of Rheumatology [25].
Collected data
Patients’ age, gender and disease characteristics (dura-
tion, anti-citrullinated protein antibody (ACPA) status)
were collected at screening. The DAS28 [26], modified
health assessment questionnaire (mHAQ) [27] and
RAID questionnaire were collected at screening, base-
line and after 4 and 12 weeks of etanercept therapy. In
addition, after 4 and 12 weeks of etanercept therapy,
the patients assessed their condition by answering the
following dichotomous question: ‘If you were to
remain during the next few months as you were during
the last 48 hours, would this be acceptable to you: yes
- no?’ [15].
At weeks 4 and 12, patients assessed their change
from baseline by answering the following questions:
‘Think about all the ways your rheumatoid arthritis has
affected you during the last 48 hours. Compared to
when you started the study, how have you been during
the last 48 hours? a) Improved, b) No change, c) Worse.
If you answered “improved” to the previous question,
how important is this improvement for you? a) Very
important, b) Moderately important, c) Slightly impor-
tant, d) Not important at all.’
Statistical analyses
Statistical analysis was conducted in two steps. We first
determined thresholds that may be used to define
responders (that is, improved patients) and patients in
an acceptable condition (that is, good/acceptable status).
The improvement threshold was determined by different
techniques:
1. An empirical technique based on proposals in the
rheumatology scientific literature (for example, an abso-
lute change of at least 1 and 2 in the 0 to 10 RAID
score; a relative change of at least 20, 30 and 50% versus
baseline) [18-20].
2. A technique based on the reliability of the RAID
score considering that a relevant change at the indivi-
dual level should be at least superior to the measure-
ment error of the technique. For this purpose, the data
collected at screening and baseline (interval during
which the disease activity was considered stable) were
used to assess the relative reliability by calculating the
intra-class coefficient of correlation (ICC) with its 95%
confidence interval (CI), the absolute reliability based on
Bland and Altman plots, presenting the 95% limits of
agreement on a graph [22], and the proposed threshold
as the smallest detectable change defined as 1.96 × SD
of the changes/√2 [28].
3. The third technique was an anchored method based
on the patient’s perspective. The external anchor was
the general question on patient perception of change in
comparison to baseline. The threshold RAID score for
improvement was determined in three different ways.
Firstly the RAID-MCII threshold was determined as the
75th percentile of the distribution of changes in RAID
score for patients perceiving a slight or moderate
improvement [14]. For this purpose, we considered as a
potential threshold the score for which 75% of the
patients in the targeted category had a value below this
score. The second analysis used the correct classification
probabilities [24]. For this purpose, we calculated the
sensitivity (percentage of patients with a measured
change in RAID score below the threshold for patients
considering their condition to be at least slightly or
moderately improved) and specificity (percentage of
patients with a change in RAID score above the
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threshold for patients considering their condition to be
at least slightly or moderately improved). This was done
for a range of possible cutoffs and this was plotted on a
graph. The choice of proposed cutoff for this analysis
was based on maximal sensitivity and specificity using
the graphic representation of correct classification prob-
abilities. The third analysis used the nonparametric
ROC curves [23]. The optimal cutoff was determined by
minimizing the number of misclassified patients. Such
evaluations were performed for the absolute and relative
changes after 4 and 12 weeks of etanercept therapy.
Several similar techniques were also used to determine
thresholds describing patients with an acceptable status/
condition according to the RAID score:
1. Empirical method with thresholds ≤ 1, ≤ 2 and ≤ 3
according to previous proposals in the rheumatology
scientific literature.
2. The anchored method based on the patient’s per-
spective using, as an external gold standard, the general
question about patients’ perceptions of their condition
during the 48 hours before the visit. The RAID thresh-
old for acceptable status was determined using the three
different analyses described for the improvement (for
example, the 75th percentile, the correct classification
properties and the ROC curve technique), with the
patients considering their condition as acceptable used
as the gold standard. All analyses were performed after
4 and 12 weeks of etanercept therapy.
We then evaluated the validity of all the proposed
thresholds. Two external anchors were chosen for this
purpose. The first was the gold standard from the
patient’s perspective: for each proposed MCII threshold,
we calculated the percentage of patients with a change
above the threshold and who considered their condition
to be at least slightly improved, among all patients who
considered their condition to be at least slightly
improved (for example, sensitivity) and also the percen-
tage of patients with a change below the threshold and
who considered their condition to be either worse,
unchanged or only slightly improved, among all patients
who considered their condition to be worse, unchanged
or only slightly improved (for example, specificity). The
positive likelihood ratio (LR) was then calculated. A LR
greater than one indicates an increased probability that
the targeted disorder is present. In our study, the use of
LR was transposed to express performance of the RAID
threshold in reflecting patients’ perspectives. Higher
values are indicative of better-performing thresholds. All
analyses were conducted at 4 and 12 weeks after initia-
tion of etanercept therapy.
A similar analysis was conducted to evaluate the valid-
ity of the proposed thresholds of the RAID score to
define an acceptable status. Here, the gold standard
anchor was based on the patient’s perspective by
analyzing the patients considering (or not) their situa-
tion during the last 48 hours as acceptable. The second
external anchor used to evaluate the validity of the pro-
posed thresholds was based on the DAS28-ESR. This
composite index is considered to be relatively physician-
oriented as it comprises one laboratory measure (ESR)
and information collected at physical examination (num-
ber of swollen and tender joints) as well as a patient-
reported outcome (patient’s global assessment). Similar
analyses (that is, evaluation of positive LR for the differ-
ent proposed thresholds evaluating the concept of
improvement and status) were conducted as described
above.
Results
Patients and study course
Of the 120 patients screened, 108 entered the study and
received at least one etanercept injection. During the 12
weeks of the trial, one patient was lost to follow-up and
ten withdrew because of side effects. The main charac-
teristics of the 108 recruited patients were as follows:
age (mean ± SD), 54 ± 13 years; 75% female; 61%
ACPA-positive; disease duration, 8 ± 7 years; CRP, 18 ±
30 mg/l, DAS28-ESR, 5.4 ± 0.8.
Determination of thresholds
Relevant improvement threshold
The reliability of the RAID score between screening and
baseline was very high (ICC = 0.85, 95% CI 0.79 to
0.90). The Bland and Altman graphic representation is
illustrated in Figure 1. Using this technique, the smallest
detectable difference (SDD) and the smallest detectable
change (SDC) in the RAID score were 1.8 and 1.3
respectively.
A graphic representation of correct classification prob-
abilities was obtained, based on patient’s opinion for the
absolute changes in RAID score after 4 weeks of etaner-
cept therapy (Figure 2). The sensitivity and specificity
for clinically relevant change was obtained for each mea-
sured difference in RAID score (0.1 per 0.1). This made
it possible to obtain the best RAID threshold with maxi-
mal true positive and minimal false negative results,
which was 1.0. A similar analysis was performed after 12
weeks of etanercept therapy and also for the relative
change after 4 and 12 weeks of etanercept therapy,
resulting in potential thresholds of 2.5, 25% and 42%
respectively (Table 2).
Figure 3 shows the ROC curves for absolute changes
in RAID score after 4 weeks of therapy, resulting in an
optimal threshold of 1.6. Similar analyses were per-
formed for the absolute changes after 12 weeks of ther-
apy and for the relative changes after 4 and 12 weeks of
therapy, resulting in potential thresholds of 3, 17% and
35% respectively (Table 2).
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Figure 2 Correct classification probability curve showing absolute change in rheumatoid arthritis impact of disease (RAID) score at
week 4.
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Figure 1 Reliability of the rheumatoid arthritis impact of disease (RAID) score shown by Bland & Altman graphic representation.
*Mean of RAID score values between screening and baseline; **difference in RAID score between screening and baseline. The data lines
represent the 95% confidence interval resulting in a smallest detectable change of 1.3 (for example, smallest detectable difference = 1.8).
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Table 2 Elaboration and evaluation of the external validity of the different potential thresholds defining a relevant
improvement in the rheumatoid arthritis impact of disease (RAID) score
ELABORATION Time of evaluation during
the studyc
EVALUATION
Proposed
thresholda
Methodological techniqueb Patient’s perspectived Physician’s perspectivee
Se Spe LR+ (95% CI) Se Spe LR+ (95% CI)
ABSOLUTE CHANGE
a. ≥ 0.2 75th percentile at week 4 Week 4 89.6 54.2 2.0 (1.3; 3.0) 100.0 29.6 1.4 (1.2; 1.7)
a. ≥ 0.2 75th percentile at week 4 Week 12 96.1 40.9 1.6 (1.1; 2.3) 93.3 17.6 1.1 (1.0; 1.3)
b. ≥ 1 Empirical/Correct classification at week 4 Week 4 75.3 75.0 3.0 (1.5; 6.1) 89.3 47.9 1.7 (1.3; 2.2)
b. ≥ 1 Empirical/Correct classification at week 4 Week 12 90.8 54.5 2.0 (1.3; 3.2) 88.9 27.5 1.2 (1.0; 1.5)
c. ≥ 1.3 SDC/75th percentile at week 12 Week 4 75.3 79.3 3.6 (1.6; 8.0) 85.7 47.9 1.6 (1.3; 2.2)
c. ≥ 1.3 SDC/75th percentile at week 12 Week 12 88.2 59.1 2.2 (1.3; 3.6) 84.4 29.4 1.2 (1.0; 1.5)
d. ≥ 1.6 ROC at week 4 Week 4 72.7 87.5 5.8 (2.0; 16.9) 85.7 53.5 1.8 (1;4; 2.5)
d. ≥ 1.6 ROC at week 4 Week 12 84.2 63.6 2.3 (1.3; 4.1) 82.2 33.3 1.2 (1.0; 1.6)
e. ≥ 2 Empirical/Correct classification at week 4 Week 4 67.5 87.5 5.4 (1.9; 15.7) 78.6 56.3 1.8 (1.3; 2.5)
e. ≥ 2 Empirical/Correct classification at week 4 Week 12 78.9 63.6 2.2 (1.2; 3.8) 77.8 37.3 1.2 (1.0; 1.6)
f. ≥ 2.5 Correct classification at week 12 Week 4 59.7 95.8 14.3 (2.1; 98.5) 71.4 64.8 2.0 (1.4; 3.0)
f. ≥ 2.5 Correct classification at week 12 Week 12 69.7 68.2 2.2 (1.2; 4.1) 77.8 52.9 1.7 (1.2; 2.3)
g. ≥ 3 ROC at week 12 Week 4 41.6 95.8 10.0 (1.4; 69.2) 57.1 77.5 2.5 (1.5; 4.3)
g. ≥ 3 ROC at week 12 Week 12 63.2 90.9 6.9 (1.8; 26.3) 71.1 64.7 2.0 (1.3; 3.1)
RELATIVE CHANGE
a. ≥ 6% 75th percentile at week 4 Week 4 88.3 54.2 1.9 (1.2; 3.0) 100.0 31.0 1.4 (1.2; 1.7)
a. ≥ 6% 75th percentile at week 4 Week 12 96.1 45.5 1.6 (1.2; 2.6) 93.3 19.6 1.2 (1.0; 1.4)
b. ≥ 17% ROC at week 4 Week 4 80.5 75.0 3.2 (1.6; 6.5) 100.0 46.5 1.9 (1.5; 2.3)
b. ≥ 17% ROC at week 4 Week 12 94.7 59.1 2.3 (1.4; 3.8) 91.1 25.5 1.2 (1.0; 1.5)
c. ≥ 20% Empirical Week 4 76.6 75.0 3.1 (1.5; 6.2) 96.4 49.3 1.9 (1.5; 2.4)
c. ≥ 20% Empirical Week 12 90.8 59.1 2.2 (1.3; 3.7) 88.9 27.5 1.2 (1.0; 1.5)
d. ≥ 25% Correct classification at week 4/75th
percentile at week 12
Week 4 76.6 75.0 3.1 (1.5; 6.2) 96.4 49.3 1.9 (1.5; 2.4)
d. ≥ 25% Correct classification at week 4/75th
percentile at with 12
Week 12 88.2 63.6 2.4 (1.4; 4.2) 88.9 33.3 1.3 (1.1; 1.7)
e. ≥ 30% 75th percentile at week 12 Week 4 67.5 87.5 5.4 (1.9; 15.7) 92.9 62.0 2.4 (1.8; 3.3)
e. ≥ 30% 75th percentile at week 12 Week 12 84.2 63.6 2.3 (1.3; 4.1) 86.7 37.3 1.4 (1.1; 1.8)
f. ≥ 35% ROC at week 12 Week 4 63.6 91.7 7.6 (2.0; 29.1) 85.7 64.8 2.4 (1.7; 3..5)
f. ≥ 35% ROC at week 12 Week 12 81.6 72.7 3.0 (1.5; 6.0) 86.7 43.1 1.5 (1.2; 2.0)
g. ≥ 42% Correct classification at week 12 Week 4 59.7 95.8 14.3 (2.1; 98.5) 82.1 69.0 2.7 (1.8; 3.9)
g. ≥ 42% Correct classification at week 12 Week 12 72.4 72.7 2.7 (1.3; 5.3) 82.2 52.9 1.7 (1.3; 2.4)
h. ≥ 50% Empirical Week 4 53.2 100.0 ND 78.6 76.1 3.3 (2.1; 5.2)
h. ≥ 50% Empirical Week 12 67.1 86.4 4.9 (1.7; 14.3) 75.6 60.8 1.9 (1.3; 2.8)
aThe values are those resulting from analysis of the data according to a specific methodology (for example, empiric smallest detectable difference, correct
classification probabilities, 75th percentile, ROC curve). bMethodological technique used in the analysis to propose a potential threshold and (in the case of the
ROC, 75th percentile and correct classification probabilities) the time point during the study (for example, 4 or 12 weeks after initiation of etanercept therapy)
such evaluation has been performed. cThe visit during the study (for example, either 4 or 12 weeks after initiation of etanercept therapy) during which the data
collected were used to evaluate the external validity of the proposed thresholds. dPatient’s perspective based on the PASS question (X, Y and Z patients
answered ‘yes’ at baseline, week 4 and week 12 respectively: Se, % patients with an absolute RAID score below the proposed cutoff who considered their
condition to be acceptable (answering ‘yes’ to the patient acceptable symptom state (PASS) question) among all patients considering their condition to be
acceptable; Spe, % patients with an absolute RAID score above the proposed cutoff who considered their condition to be unacceptable (answering’ no’ to the
PASS question) among all patients considering their condition to be unacceptable. ePhysician’s perspective based on the low disease activity defined by the
disease activity score-erythrocyte sedimentation rate (DAS-ESR) < 3 (X, Y, and Z patients had a DAS < 3.2 at baseline, week 4 and week 12 respectively): Se, %
patients with an absolute RAID score below the proposed cutoff and in low disease activity (for example, DAS28-ESR ≤ 3.2) at week 12 among all patients with
low disease activity at week 12: Spe, % patients with an absolute RAID score above the proposed cutoff and with at least moderately active disease (for example,
DAS28-ESR ≥ 3.2) at week 12 among all patients with at least moderately active disease at week 12. ROC, receiver operating characteristic; LR+, positive
likelihood ratio.
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Figure 4 plots the distribution of absolute change from
baseline in RAID score after 4 weeks of etanercept ther-
apy among the 30 patients considering their condition
to be slightly or moderately improved. Using this techni-
que, 75% of these patients had a RAID score below 0.2,
and therefore 0.2 was proposed as a potential optimal
threshold (Figure 5). Similar analyses were performed to
evaluate the absolute changes after 12 weeks and also
the relative changes after 4 and 12 weeks, resulting in
potential thresholds of 1.3, 6% and 25% respectively
(Table 2).
Table 2 and Figures 5 and 6 summarize the proposed
thresholds resulting from these different techniques.
These ranged from 0.2 (75th percentile technique at
week 4) to 3 (ROC technique at week 12) for defining a
minimum clinically important improvement in the abso-
lute change in RAID score and ranged from 6% (75th
percentile technique at week 4) to 50% (empirical tech-
nique) for a MCII in the relative changes in the RAID
score.
Threshold for defining an acceptable status
Table 3 and Figure 7 summarize the thresholds pro-
posed by the different techniques used, ranging from a
minimal score of 1 (empirical technique) to 4.2 (75th
percentile and ROC technique at week 4) for the defini-
tion of a patient-acceptable symptom state in the RAID
score.
Evaluation of proposed thresholds
Evaluation of improvement thresholds
Table 2 summarizes the sensitivity, specificity and posi-
tive LR for each proposed threshold for the two external
anchors (for example, patient’s perspective and DAS28-
ESR). These analyses showed that the positive LR was
above 1 for all the proposed thresholds (Figure 5). How-
ever, the highest values were observed for a threshold of
3 for the absolute change (with a corresponding positive
LR of 6.9 and 2.0 for the patient’s perspective and
DAS28-ESR external gold standards respectively, at
week 12). Concerning the relative changes, the highest
positive LR (4.9 and 1.9 for the patient’s perspective and
DAS28-ESR external gold standards respectively, at
week 12) were observed for an improvement of at least
50% (Figure 6).
Evaluation of acceptable status thresholds
Table 3 summarizes the sensitivity, specificity and posi-
tive LR for each proposed threshold and for the 2 exter-
nal anchors (for example, patient’s perspective and
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Figure 3 Receiver operating characteristic curve showing absolute change in rheumatoid arthritis impact of disease (RAID) score at
week 4.
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DAS28-ESR). As for the improvement thresholds, all the
thresholds proposed for defining an acceptable symp-
tom-state had a corresponding positive LR > 1 (see Fig-
ure 7). For a maximum score of 2, the corresponding
positive LR had the highest positive LR (for example,
10.1 and 3.4 for the patient’s perspective and DAS28-
ESR external gold standards respectively, at week 12).
Discussion
This study clearly shows that the threshold value for a
continuous variable, defining a relevant improvement or
an acceptable symptom state, closely depends on the
measurement technique. This first observation
prompted us to perform a systematic validation of the
proposed thresholds. In this study, we evaluated the
validity of each proposed threshold by calculating the
probability of being considered in good condition, by
using external gold standards for the group of patients
that were below or above the proposed threshold. We
used two external gold standards reflecting both the
patient’s perspective (the patient’s global assessment)
and the physician’s perspective (the DAS28-ESR) and
calculated the positive LR: the best threshold was
considered to be that with the highest observed positive
LR. Using this methodology, we were able to propose an
absolute change of at least 3, a relative change of at
least 50%, and a maximum score of 2, as optimal thresh-
olds for the RAID score, to define an absolute and rela-
tive MCII, and an acceptable symptom-state
respectively.
This study has some weaknesses, but also several
strengths. The very wide range of threshold values pro-
posed using different methodologies raises the question
of the optimal way to address this issue. All the techni-
ques used in this study have been previously adopted,
though no consensus has been reached in the field of
clinical epidemiology [10-21]. This can be easily
explained by the different rationales of each technique:
the empirical technique involves asking physicians to
propose relevant thresholds based on the simplicity of
their proposal or their experience [20]. The aim of
another technique is to avoid proposing a value below
the measurement error of the outcome measure, as any
interpretation of results using a threshold below the
noise due to this measurement error is hazardous
[22,23]. Finally, the techniques using an external anchor
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Figure 4 Distribution of the absolute changes in rheumatoid arthritis impact of disease (RAID) score from baseline to week 4 in
patients considering their condition to be slightly or moderately improved. EULAR, European League Against Rheumatism.
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Figure 5 Proposals and evaluation of different thresholds for defining a clinically meaningful improvement in an absolute change in
the rheumatoid arthritis impact of disease (RAID) score. a. Proposals of threshold according to different techniques and different times of
evaluation. b. Evaluation of external validity (versus DAS28-ESR) of different proposed thresholds. c. Evaluation of external validity (versus patient’s
global assessment) of different proposed thresholds. *Thresholds, proposal based on the following techniques and time of evaluation: a, 75th
percentile technique at week 4; b, empirical technique and correct classification at week 4; c, smallest detectable change and 75th percentile at
week 12; d, ROC technique at week 4; e, empirical technique and correct classification at week 4; f, correct classification at week 12; g, ROC
technique at week 12. +Positive likelihood ratio (higher values are indicative of better performing thresholds. See Methods for further
explanation). DAS28-ESR, Disease Activity Score 28-erythrocyte sedimentation rate; ROC, receiver operating characteristic.
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Figure 6 Proposals and evaluation of different thresholds for defining a clinically meaningful improvement in a relative change in the
rheumatoid arthritis impact of disease (RAID) score. a. Proposals of threshold according to different techniques and different times of
evaluation. b. Evaluation of external validity (versus DAS28-ESR) of different proposed thresholds. c. Evaluation of external validity (versus patient’s
global assessment) of different proposed thresholds. *Thresholds, proposal based on the following technique and time of calculation: a, 75th
percentile technique at week 4; b, ROC technique at week 4; c, empirical technique; d, correct classification at week 4 and 75th percentile at
week 12; e, 75th percentile at week 12; f, ROC technique at week 12; g, correct classification at week 12; h, empirical technique. +Positive
likelihood ratio (higher values are indicative of better performing thresholds. See Methods for further information). DAS28-ESR, Disease Activity
Score 28-erythrocyte sedimentation rate; ROC, receiver operating characteristic.
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are also very relevant [14,15]. Although the validity of
this external anchor may be questioned (here we used
the previously reported gold standard MCII and PASS
questions, which might raise the issue of a circular rea-
soning), these techniques make it possible to select the
optimal threshold based on the arguments for and
against, favoring sensitivity (for example, 75th percentile
technique [14,15]), sensitivity and specificity (for exam-
ple, ROC curve and correct probability technique
[23,24]). In this study therefore, we decided to use all
the different techniques in a uniform group of patients
(for example, active definite RA requiring a TNF
blocker) receiving the same TNF blocker (etanercept).
Despite this fact, we observed a very wide variability in
the thresholds proposed by these analyses. From our
point of view, such variability justifies a systematic eva-
luation of the validity of any proposed threshold and the
main question is to define the optimal methodology for
evaluating such validity. In this study, we approached
this question by calculating the capacity of a proposed
threshold to adequately classify a patient by considering
previously validated external anchors from both a
patient’s perspective and a physician’s perspective. The
MCII and PASS questions were considered to be a gold
standard anchor for the patient’s perspective [14,15].
Because we also used the MCII and PASS questions for
the elaboration of such thresholds, one might be con-
cerned by the potential circular reasoning of this
approach. This is why we decided to use not only this
external anchor but also another one (the DAS28),
which is considered a physician’s perspective [26], while
evaluating a patient. We then calculated the positive LR.
This approach, using two different external anchors
resulted in quite good concordance between the two
Table 3 Elaboration and evaluation of the external validity of the different potential thresholds defining an
acceptable status in the rheumatoid arthritis impact of disease (RAID) score
ELABORATION Time of evaluation during the
studyc
EVALUATION
Proposed
thresholda
Patient’s perspectived Physician’s
perspectivee
Se Spe LR+ (95% CI) Se Spe LR+ (95%
CI)
a. ≤ 1 Empirical Week 4 21.2 94.3 3.7 (0.9; 15.4) 32.1 93.0 4.6 (1.7;
12.4)
a. ≤ 1 Empirical Week 12 25.3 100.0 ND 31.1 90.2 3.2 (1.2; 8.1)
b. ≤ 2 Empirical Week 4 36.4 91.4 4.2 (1.4; 13.1) 50.0 84.5 3.2 (1.7; 6.2)
b. ≤ 2 Empirical Week 12 50.6 95.0 10.1 (1.5; 69.3) 66.7 80.4 3.4 (1.9; 6.2)
c. ≤ 3 Empirical Week 4 54.5 82.9 3.2 (1.5; 6.8) 82.1 76.1 3.4 (2.2; 5.4)
c. ≤ 3 Empirical Week 12 69.6 80.0 3.5 (1.4; 8.5) 80.0 56.9 1.9 (1.3; 2.6)
d. ≤ 3.3 75th percentile at week 12 Week 4 63.6 77.1 2.8 (1.5; 5.3) 89.3 67.6 2.8 (1.9; 3.9)
d. ≤ 3.3 75th percentile at week 12 Week 12 77.2 80.0 3.9 (1.6; 9.4) 82.2 47.1 1.6 (1.2; 2.1]
e. ≤ 3.7 Correct classification at week 12 Week 4 69.7 77.1 3.0 (1.6; 5.7) 92.9 62.0 2.4 (1.8; 3.3)
e. ≤ 3.7 Correct classification at week 12 Week 12 79.7 80.0 4.0 (1.6; 9.6) 84.4 45.1 1.5 (1.2; 2.0)
f. ≤ 4 ROC week 12 Week 4 72.7 77.1 3.2 ([1.7; 6.0) 92.9 59.2 2.3 (1.7; 3.1)
f. ≤ 4 ROC week 12 Week 12 86.1 80.0 4.3 (1.8; 10.4) 86.7 37.3 1.4 (1.1; 1.8)
g. ≤ 4.1 Correct classification week 4 Week 4 74.2 77.1 3.2 (1.7; 6.1) 92.9 57.7 2.2 (1.6; 2.9)
g. ≤ 4.1 Correct classification week 4 Week 12 86.1 75.0 3.4 (1.6; 7.4) 86;7 35.3 1.3 (1.1; 1.7)
h. ≤ 4.2 75th percentile at week 4/ROC
week 4
Week 4 77.3 74.3 3.0 (1.7; 5.4) 92.9 53.5 2.0 (1.5; 2.6)
h. ≤ 4.2 75th percentile at week 4/ROC
week 4
Week 12 87.3 75.0 3.5 (1.6; 7.5) 86.7 33.3 1.3 (1.0; 1.6)
aThe values are those resulting from analysis of the data according to a specific methodology (for example, empiric smallest detectable difference, correct
classification probabilities, 75th percentile, ROC curve). bMethodological technique used in the analysis to propose a potential threshold and (in the case of the
ROC, 75th percentile and correct classification probabilities) the time point during the study (for example, 4 or 12 weeks after initiation of etanercept therapy)
such evaluation has been performed. cThe visit during the study (for example, either 4 or 12 weeks after initiation of etanercept therapy) during which the data
collected were used to evaluate the external validity of the proposed thresholds. dPatient’s perspective based on the patient acceptable symptom state (PASS)
question (X, Y and Z patients answered ‘yes’ at baseline, week 4 and week 12 respectively: Se, % patients with an absolute RAID score below the proposed cutoff
who considered their condition to be acceptable (answering ‘yes’ to the PASS question) among all patients considering their condition to be acceptable; Spe, %
patients with an absolute RAID score above the proposed cutoff who considered their condition to be unacceptable (answering ‘no’ to the PASS question)
among all patients considering their condition to be unacceptable. ePhysician’s perspective based on the low disease activity defined by the Disease Activity
Score-erythrocyte sedimentation rate (DAS-ESR) < 3 (X, Y, and Z patients had a DAS < 3.2 at baseline, week 4 and week 12 respectively): Se, % patients with an
absolute RAID score below the proposed cutoff and in low disease activity (for example, DAS28-ESR ≤ 3.2) at week 12 among all patients with low disease
activity at week 12: Spe, % patients with an absolute RAID score above the proposed cutoff and with at least moderately active disease (for example, DAS28-ESR
≥ 3.2) at week 12 among all patients with at least moderately active disease at week 12. ROC, receiver operating characteristic; LR+, positive likelihood ratio.
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Figure 7 Proposals and evaluation of different thresholds for defining an acceptable status according to the rheumatoid arthritis
impact of disease (RAID) score. a. Proposals of threshold according to different techniques and different times of evaluation. b. Evaluation of
external validity (versus DAS28-ESR) of different proposed thresholds. c. Evaluation of external validity (versus patient’s global assessment) of
different proposed thresholds. *Thresholds, proposal based on the following technique and time of calculation: a, 75th percentile technique at
week 4; b, ROC technique at week 4; c, empirical technique; d, correct classification at week 4 and 75th percentile at week 12; e, 75th percentile
at week 12; f, ROC technique at week 12; g, correct classification at week 12; h, empirical technique. +Positive likelihood ratio (higher values are
indicative of better performing thresholds. See Methods for further information). DAS28-ESR, Disease Activity Score 28-erythrocyte sedimentation
rate; ROC, receiver operating characteristic.
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analyses for each proposed threshold, strengthening our
finding. This agrees with the results of a previous study
suggesting that the PASS corresponds to moderate dis-
ease activity [29]. The data presented in the figures sug-
gest also that the most stringent thresholds are also the
most valid, at least with regard to our definition of
external validity.
A weakness of this study was the fact that we were
unable to evaluate the discriminant capacity of the pro-
posed thresholds in order to validate them. Another
potential weakness is that the proposed thresholds were
defined in a single study with a relatively small sample
size. On the other hand, the strength of this study is
that all these different analyses of the definition of
thresholds for a continuous variable were performed on
a uniform group of patients. Despite these points, using
our methodology and calculating the positive LR using
two external anchors, we found a difference between the
different thresholds, so that we were able to propose an
absolute change of 3 points and a relative change of
50% for defining a clinically relevant improvement, and
a maximum score of 2 for defining an acceptable status.
Further studies in different patient populations, evaluat-
ing different facets of validity (including for example,
the evaluation of discriminatory capacity), are necessary
to confirm these proposals.
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